News Sentiment

ENLV sentiment intelligence

Enlivex Therapeutics Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.86 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

83/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-13.3% over one week, -31.8% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 83/100 classification
One-week reaction -13.3% Price reacting lower
Trend fit Trend inactive -31.8% over four weeks
Fair value -68.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 36
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 11
TradingKey 8
simplywall.st 3
The Manila Times 2
GuruFocus 2
MT Newswires 2
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 13
Balance sheet 3
Capital return 2
Analyst action 1
Deals and strategy 1
Guidance 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-59 of 59
TradingKey Direct company coverage

Enlivex Therapeutics Ltd (ENLV) Institutional Confidence

This article provides an "Institutional Confidence" overview for Enlivex Therapeutics Ltd (ENLV), indicating a score of 3.00, unchanged from the previous score as of June 18, 2026. It highlights institutional shareholding data, specifically mentioning Shai A. Novik's stake of 858

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 06:19
Source
TradingKey
TradingKey Direct company coverage

Enlivex Therapeutics Ltd (ENLV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides an overview of Enlivex Therapeutics Ltd (ENLV), focusing on its revenue breakdown. However, it indicates that relevant data regarding business segments, regional revenue, and profit contribution for ENLV have not yet been disclosed by the com

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 21:40
Source
TradingKey
TradingKey Direct company coverage

Enlivex Therapeutics Ltd (ENLV) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Enlivex Therapeutics Ltd (ENLV) stock information, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends in the past five years and has no record of stock splits. The page also displa

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 21:40
Source
TradingKey
TradingKey Direct company coverage

Enlivex Therapeutics Ltd (ENLV) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Enlivex Therapeutics Ltd (ENLV), listing major shareholders such as Gems Foundation, Token Factory, and Sobrinia Ltd, along with their respective proportions. It also presents a breakdown of shareholder types, indicating that corp

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 20:40
Source
TradingKey
Investing.com Australia Direct company coverage

Enlivex receives Australian patent for osteoarthritis treatment

Enlivex Ltd. has been granted an Australian patent for its Allocetra therapy to treat osteoarthritis, providing intellectual property protection in Australia through at least 2040. This news comes as the company's shares trade near their 52-week low, and they are currently conduc

Tone
Positive 72/100
Event
Market update
Published
16 Jun 2026 06:39
Source
Investing.com Australia
Investing.com UK Direct company coverage

Enlivex receives Australian patent for osteoarthritis treatment By Investing.com

Enlivex Ltd. has been granted an Australian patent for its Allocetra therapy for osteoarthritis, extending intellectual property protection until at least 2040. This news comes as the company's shares trade near a 52-week low, despite positive clinical trial data for Allocetra in

Tone
Positive 67/100
Event
Market update
Published
15 Jun 2026 17:39
Source
Investing.com UK